Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline
Webcast to be Held on
The event will feature presentations and discussions with:
Jamie Fergie, MD, FAAP, FIDSA, FSHEA – Medical Director, Global Institute for Hispanic Health, Professor of Pediatrics, Texas A&M Universityand Director, Infectious Diseases, Driscoll Children’s Hospital
Tom Wilkinson, MA (Cantab), MBBS, PhD, FRCP, FERS – Professor of Respiratory Medicine and Associate Dean, University of Southamptonand Faculty of Medicine, Southampton General Hospital
The event will be led by
Complete speaker biographies can be found on the Event registration page here.
Event details are as follows:
Respiratory Syncytial Virus: The Evolving Treatment Landscape
Date and Time:
Webcast Link: Register
A webcast of the event will be available on the investor relations page of the
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).
Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (
Media and Investors Contact